# Sermorelin: Frequently Asked Questions

> Sermorelin FAQ — 29 questions answered directly from the peer-reviewed research record: mechanism, dosage, side effects, half-life, regulatory status, and comparisons.

## Mechanism and classification

**What is Sermorelin?**
Sermorelin (GHRH 1-29 NH2) is a synthetic 29-amino-acid analog of endogenous growth hormone-releasing hormone; it stimulates the anterior pituitary to release GH and has been studied for GH deficiency and aging-related GH decline. Its molecular weight is approximately 3,357.9 Da. Sermorelin acetate (Geref) held FDA approval for pediatric GH deficiency until 2008 [1][2].

**What does Sermorelin do to the body?**
Sermorelin binds GHRH receptors in the anterior pituitary, stimulating synthesis and pulsatile release of endogenous growth hormone; downstream effects include IGF-1 elevation and associated anabolic signaling [6]. In the Vitiello 2001 aging study, 5-6 months of bedtime sermorelin elevated IGF-1 by approximately 35%, reduced visceral body fat, increased lean body mass by approximately 5% on DEXA, and improved psychomotor processing speed by 5-7% [4].

**Is Sermorelin a steroid?**
No. Sermorelin is a peptide hormone analog — a 29-amino-acid chain — not a steroid. It operates on the GHRH receptor (a G protein-coupled receptor), not via steroid hormone receptors [6].

**Is sermorelin a peptide?**
Yes. Sermorelin is a 29-amino-acid synthetic peptide — specifically a truncated analog of the 44-residue endogenous GHRH, retaining full biological activity at the GHRH receptor [6]. Its very short plasma half-life of approximately 4.3 minutes via IV confirms its susceptibility to proteolytic degradation in plasma [7].

**How does sermorelin work?**
Sermorelin binds and activates the pituitary GHRH receptor (GHRHR), stimulating cAMP-mediated transcription of GH mRNA and subsequent pulsatile GH secretion; it preserves pituitary reserve unlike exogenous GH [6]. The cAMP signal activates PKA, which phosphorylates CREB, inducing Pit-1 transcription factor synthesis and driving GH gene expression in pituitary somatotrophs [6].

## Dosage and administration

**How much sermorelin per day?**
Published adult studies employ doses ranging from approximately 14 mcg/kg (~1 mg) at bedtime (Vitiello 2001) [4] to 1 mg twice daily (Koutkia 2004 JAMA RCT) [10]. Pediatric GHD trials used 30 mcg/kg at bedtime [2] and 20 mcg/kg twice daily [3]. These are documented research-population doses, not recommendations for any individual.

**How many days a week do you take sermorelin?**
Published protocols typically employ daily subcutaneous administration. The Vitiello 2001 aging study and the Geref pediatric multicenter trial both used once-daily bedtime dosing [2][4].

**Why take sermorelin at night?**
Endogenous GH secretion is highest during slow-wave sleep; evening sermorelin administration is designed to amplify the physiological nocturnal GH pulse [8]. A Kerkhofs 1993 study showed GHRH bolus at 0.3 mcg/kg during late sleep produced a nearly 10-fold increase in slow-wave sleep in the third REM period [8].

**Where to inject sermorelin?**
Subcutaneous injection into abdominal, thigh, or deltoid adipose tissue is the route used in clinical trials [4][10].

**How long does it take for sermorelin to work?**
Acute GH pulse is detectable within 30-60 minutes of injection [7][8]. Functional outcomes emerge over 4-12 weeks of continuous administration in trials: the Vitiello 2001 study measured outcomes at 5-6 months [4]; the Thorner 1996 pediatric study showed accelerated height velocity by 6 months [2]; the Koutkia 2004 JAMA RCT measured body composition at 12 weeks [10].

**How long does sermorelin stay in your system?**
Sermorelin has a very short plasma half-life of approximately 4.3 ± 1.4 minutes via IV (Soule 1994) [7]. The GH pulse induced by sermorelin peaks at 30-60 minutes and returns to baseline within 3-4 hours.

## Safety and side effects

**Is sermorelin safe?**
Clinical trials characterize sermorelin as generally well-tolerated; serious adverse events are rare [14]. The Geref multicenter pediatric trial (110 children, 12 months) found no adverse metabolic changes, normal fasting glucose, and appropriate IGF-I levels [2].

**What are the downsides of Sermorelin?**
Reported adverse effects in studies include injection-site reactions (erythema, pruritus), headache, flushing, dizziness, nausea, arthralgia, and peripheral edema [14]. Subcutaneous bioavailability is less than 4%, so injection is the only effective administration route [14].

**Are there long-term side effects of Sermorelin?**
Long-term safety data in humans is limited; Walker 2006 reported sustained tolerability in the 5-6 month Vitiello aging study and the 12-month Geref pediatric trials [5][2][16]. Extended placebo-controlled studies beyond 12 months are absent from the published literature since the 2008 Geref market withdrawal.

**Who should not use Sermorelin?**
Studies exclude subjects with active malignancy, hypothyroidism, or hypersensitivity to GHRH analogs [2][14]. Athletes subject to WADA code cannot use sermorelin without a Therapeutic Use Exemption: it is classified S2 (Prohibited at all times) [1].

**What not to mix with Sermorelin?**
Glucocorticoids may blunt GH response by increasing hypothalamic somatostatin tone [13]. The Sigalos 2017 study observed blunted IGF-1 response in subjects using aromatase inhibitors or tamoxifen concurrently with the combination secretagogue protocol [9].

## Efficacy and outcomes

**Does sermorelin work?**
Multiple placebo-controlled trials demonstrate statistically significant GH and IGF-1 elevation. The Koutkia 2004 JAMA RCT (n=31) showed significant IGF-1 elevation (104 vs 6 ng/mL placebo, P=0.004) and body composition improvements [10]. The Geref multicenter pediatric trial showed 74% favorable response in 110 children in year one [2].

**Is sermorelin worth it?**
Research outcomes are favorable for GH/IGF-1 elevation and tolerability; functional benefits (sleep, body composition) are supported by controlled trials though long-term data remains limited [4][5][10].

**Does sermorelin burn belly fat?**
Elevated GH/IGF-1 from GHRH stimulation is associated with reduced visceral adipose tissue in multiple trials. The Vitiello 2001 aging study showed approximately 5% reduction in body fat, primarily visceral abdominal fat [4]. The Koutkia 2004 JAMA RCT showed 19.2 cm² VAT decrease versus 2.3 cm² increase in controls [10].

**Does sermorelin help with weight loss?**
Indirect evidence via GH/IGF-1-mediated lipolysis: the Vitiello 2001 aging study showing ~5% body fat reduction [4] and the Koutkia 2004 JAMA RCT showing trunk fat reduction of 0.4 kg versus +0.2 kg placebo [10].

**What does sermorelin do for men?**
The Sigalos 2017 study in 14 hypogonadal men showed IGF-1 increase from 159.5 to 239.0 ng/mL (P<0.0001) and significant testosterone and free testosterone increases over 134 days [9].

**Can women take sermorelin?**
Female subjects appear in multiple published trials. Estrogen status significantly modulates the response: non-estrogen replacement therapy women showed approximately 30% IGF-1 increase and 5% body fat reduction, while estrogen replacement therapy women showed vigorous GH response with less than 10% IGF-1 increment — due to hepatic GH resistance from oral estrogen's first-pass effect [4][18].

**Does sermorelin increase testosterone?**
Sermorelin acts on the GH/IGF-1 axis, not directly on the HPG axis. The Sigalos 2017 study using a combination secretagogue protocol that included sermorelin showed significant testosterone and free testosterone increases [9]. Isolated sermorelin-only testosterone data is limited.

## Regulatory and comparative

**Is sermorelin FDA approved?**
Sermorelin acetate (Geref) held FDA approval for pediatric GH deficiency until 2008 voluntary market withdrawal; it is not currently FDA-approved for any indication [1]. The withdrawal was a manufacturing decision by EMD Serono, not a safety recall.

**Is sermorelin legal?**
Sermorelin is prescription-only in the US; it is not a controlled substance in most countries [1]. It is prohibited by WADA/USADA in competitive sports under S2 (Peptide Hormones) — prohibited in-competition and out-of-competition [1].

**Why is Sermorelin banned?**
USADA and WADA prohibit Sermorelin under S2 peptide hormones due to its GH-stimulating activity and performance enhancement potential [1]. The compound was not banned from the US market by the FDA — it was voluntarily withdrawn in 2008 by its manufacturer due to discontinuation of the active pharmaceutical ingredient.

**What is safer, sermorelin or HGH?**
Because Sermorelin stimulates endogenous GH release through pituitary feedback mechanisms, it preserves natural GH pulsatility and auto-regulation; exogenous HGH bypasses pituitary feedback [5]. The Stanley 2011 JCEM trial confirmed GHRH analog administration increased GH pulsatility without impairing insulin sensitivity, unlike exogenous rhGH [11].

**What is the sermorelin vs ipamorelin difference?**
Sermorelin is a GHRH analog acting on GHRHR; ipamorelin is a ghrelin mimetic acting on GHS-R1a. Both elevate GH but via distinct receptor pathways — combinatorial protocols are studied in some trials [15][9]. Ipamorelin is notable for GH selectivity without cortisol or ACTH elevation [15].

**Is sermorelin like tirzepatide?**
Mechanistically distinct: Sermorelin stimulates GH via GHRH receptor agonism; tirzepatide acts on GIP and GLP-1 receptors to modulate insulin and satiety [6]. Different receptor systems, different physiological axes, different research applications.

---

A bright, plain-spoken digest of the peer-reviewed Sermorelin record — GHRH(1-29) literature sorted and cited, no clinic behind the name.